Hangzhou Leap Chem Co., Ltd. is one of the most professional manufacturers and suppliers of rifabutin丨cas 72559-06-9 in China. Welcome to wholesale bulk high quality chemical products at competitive price from our factory. If you have any enquiry about custom service, please feel free to email us.
Specifications
| Grade: | USP38 |
| Appearance: | Purple red to purple black powder |
| Assay: | 95.0%~102% |
| Solubility: | Soluble in methanol and chloroform. Slightly soluble in ethanol. Practically insoluble in water. |
| Identification: | A, B Positive |
| Related substances: | Each individual impurity at about RRT 0.5, 0.6, 0.8 and 1.4 with respect to rifabutin: 1.0% max |
| Each other individual impurity: | 0.5% max |
| Sum of impurities: | 0.3% max |
| Limit of N-isobutylpiperidone: | 0.5% max |
| Water: | 2.5% max |
Transport Information
|
Parameter |
Specification |
|
UN Number |
|
|
Class |
|
|
Packing Group |
|
|
H.S. Code |
2941903000999 |
|
Stability & Reactivity |
The product is chemically stable under standard ambient conditions. |
|
Storage |
Store in freezer, under -20°C;Store under inert gas |
|
Condition to Avoid |
Heat |
|
Package |
Manufacturing Information
|
Parameter |
Specification |
|
Capacity |
|
|
Frequency |
|
|
Main Export Countries |
|
|
Capacity/Batch |
|
|
Experience |
Production since 2009 |
|
Stock |
Applications
1. Treatment of Mycobacterial Infections
Primary use: Treatment and prevention of Mycobacterium avium complex (MAC) infections, especially in immunocompromised patients (e.g., those with HIV/AIDS).
Also effective against Mycobacterium tuberculosis, making it a secondary treatment option for tuberculosis (TB).
2. HIV-Associated Opportunistic Infection Management
Rifabutin is a preferred antibiotic for MAC prophylaxis in patients with advanced HIV (CD4 < 50 cells/μL), due to its:
High intracellular penetration
Broad antimycobacterial activity
Less induction of cytochrome P450 enzymes compared to rifampin
3. Alternative to Rifampin in TB Therapy
Used when rifampin cannot be administered due to drug-drug interactions, especially in:
HIV patients on protease inhibitors or NNRTIs
Organ transplant recipients
Offers similar bactericidal activity against M. tuberculosis, but with a longer half-life and more favorable interaction profile.
4. Off-Label and Investigational Uses
Studied in the treatment of Helicobacter pylori infections.
Considered in drug-resistant or relapsed TB cases where conventional rifamycins are unsuitable.
Benefits
🛡️ Broad-Spectrum Antimycobacterial Activity
Effective against both typical and atypical mycobacteria, particularly MAC and TB.
💊 Oral Administration
Taken orally, improving patient compliance in outpatient settings.
🔄 Lower CYP3A4 Induction
Compared to rifampin, rifabutin causes fewer drug interactions, which is vital for patients on complex regimens (e.g., antiretrovirals, immunosuppressants).
🕒 Long Half-Life
Enables once-daily dosing or intermittent therapy, beneficial for prophylactic treatments and simplified regimens.
👥 Use in Immunocompromised Patients
Demonstrates strong efficacy and safety in HIV/AIDS patients, reducing MAC-related morbidity.
Conclusion
Rifabutin (CAS 72559-06-9) is a potent, broad-spectrum antibiotic primarily used for preventing and treating mycobacterial infections, particularly MAC in HIV/AIDS patients and tuberculosis in those requiring alternative rifamycin therapy. Its unique pharmacological advantages-such as oral availability, low interaction potential, and long half-life-make it a crucial tool in managing complex infectious diseases. Despite some side effects, rifabutin remains essential in modern antimicrobial regimens, especially where patient-specific factors demand flexible and less interactive options.
